Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1909490 Target Snapshot

Interleukin-1 beta · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
350Compounds
26Assays
2Approved Drugs
472.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Interleukin-1 beta shows approved-linked disease relevance led by cryopyrin-associated periodic syndrome. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P01584. Start with cryopyrin-associated periodic syndrome, then reuse UniProt P01584 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with cryopyrin-associated periodic syndrome, then reuse UniProt P01584 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 2 linked drugs
Open source guide
Disease program
cryopyrin-associated periodic syndrome

Interleukin-1 beta shows approved-linked disease relevance led by cryopyrin-associated periodic syndrome. 5 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.

Start review with cryopyrin-associated periodic syndrome because it currently carries approved-linked support. Linked drugs include CANAKINUMAB, RILONACEPT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 2 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Interleukin-1 beta as ChEMBL target CHEMBL1909490, mapped to UniProt P01584. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Interleukin-1 beta
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL1909490
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P01584
Interleukin-1 beta
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Interleukin-1 beta is the right protein anchor across sources, using UniProt P01584 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why cryopyrin-associated periodic syndrome is currently framed as approved-linked support. It currently carries 2 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameInterleukin-1 beta
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP01584
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelInterleukin-1 beta
UniProt AccessionP01584
Component TypeProtein
Sequence Length269 aa

Interleukin-1 beta

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Interleukin-1 beta, mapped to UniProt P01584. Sequence length is 269 aa.

Mapped IDP01584
Review nameInterleukin-1 beta
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Interleukin-1 beta shows approved-linked disease relevance led by cryopyrin-associated periodic syndrome. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
cryopyrin-associated periodic syndrome
2 linked drugs · 2 direct · 2 efficacy
Linked drugCANAKINUMAB
Linked drugRILONACEPT
Approved-linked Approved
familial Mediterranean fever
2 linked drugs · 2 direct · 2 efficacy
Linked drugCANAKINUMAB
Linked drugRILONACEPT
Approved-linked Approved
immune system disease
2 linked drugs · 2 direct · 2 efficacy
Linked drugCANAKINUMAB
Linked drugRILONACEPT
Approved-linked Approved
juvenile idiopathic arthritis
2 linked drugs · 2 direct · 2 efficacy
Linked drugCANAKINUMAB
Linked drugRILONACEPT
Approved-linked Approved
Muckle-Wells syndrome
2 linked drugs · 2 direct · 2 efficacy
Linked drugCANAKINUMAB
Linked drugRILONACEPT
Approved-linked Approved
CINCA syndrome
1 linked drug · 1 direct · 1 efficacy
Linked drugCANAKINUMAB
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with cryopyrin-associated periodic syndrome because it currently carries approved-linked support. Linked drugs include CANAKINUMAB, RILONACEPT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasecryopyrin-associated periodic syndrome
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

2
Approved
1
Phase III
1
Phase II
Assay Mix

Activity Type Distribution

IC50457.0
KI11.0
KD4.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5414596 9.4 IC50 0.4 Preclinical
CHEMBL5426651 9.4 IC50 0.4 Preclinical
CHEMBL3989927 9.34 IC50 0.46 Clinical
CHEMBL5992744 9.22 IC50 0.6 Preclinical
CHEMBL5774519 9.15 IC50 0.7 Preclinical
CHEMBL5433380 9.1 IC50 0.8 Preclinical
CHEMBL5797061 9.1 IC50 0.8 Preclinical
CHEMBL5906571 9.1 IC50 0.8 Preclinical
CHEMBL5910216 9.1 IC50 0.8 Preclinical
CHEMBL5991941 9.1 IC50 0.8 Preclinical
Distribution

pChEMBL Value Distribution

7
5.0
5
5.5
39
6.0
153
6.5
158
7.0
9
7.5
14
8.0
13
8.5
14
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

POMALIDOMIDE
CHEMBL43452
Approved 2013
Properties Compare Identifier
LENALIDOMIDE
CHEMBL848
Approved 2005
Properties Compare Identifier
Assay Landscape

Assay Landscape

26
Total Assays
295
Tested Compounds
1
Assay Types
Binding — 26 assays, 295 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 13 15 6.1
cell-based format 8 163 6.8
assay format 5 117 7.5

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine